Chardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock

  • Chardan has initiated coverage on Oncorus Inc ONCR with a Buy rating and a price target of $5.
  • The analysts based it on the company's commercial potential with its lead oncolytic virus immunotherapy ONCR-177 from its HSV platform.
  • Oncorus' HSV platform utilizes the herpes simplex virus (HSV) type 1 backbone that incorporates more transgenes, retains the ability to replicate in tumor cells, and has orthogonal safety strategies to attenuate viral replication in healthy tissues. 
  • Related: Why Did Oncorus Shares Slump To 52-Week Low Today?
  • The company's lead program, ONCR-177, is being evaluated as a monotherapy and combined with Merck & Co Inc's MRK Keytruda in an ongoing phase I study for solid tumors. 
  • Chardan notes that treatment in the monotherapy arm was "well tolerated with no dose-limiting toxicities," and the recommended phase 2 dose was determined as 4e8 PFU/dose in 4 mL.
  • The analyst projects an initial product launch for the program in 2026. Using a probability of success of 25% for the program, Chardan estimates ONCR-177 netting ~$230 million in probability-adjusted global sales in 2030.
  • Price Action: ONCR shares are down 3.40% at $1.57 during the market session on the last check Wednesday.
Price Target
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CareInitiationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!